Cytokinetics (NASDAQ:CYTK) Price Target Raised to $101.00 at Royal Bank Of Canada
Royal Bank of Canada has increased its price target for Cytokinetics (NASDAQ:CYTK) to $101.00 from $95.00, maintaining an "outperform" rating and implying a potential 47% upside. This comes amidst other analysts also raising their targets, contributing to a "Moderate Buy" consensus with an average price target of $88.28. Despite this, company insiders have recently been net sellers of the stock, offloading shares worth approximately $9.8 million in the last three months.
RBC Raises Price Target on Cytokinetics to $101 From $95, Keeps Outperform, Speculative Risk
RBC Capital Markets has increased its price target for Cytokinetics (CYTK) to $101 from $95, while maintaining an "Outperform" rating with a "Speculative Risk" designation. This adjustment highlights a positive outlook from the analyst firm for the cardiovascular biopharmaceutical company. Cytokinetics continues to focus on developing and commercializing muscle biology-directed drug candidates for debilitating heart conditions.
Earnings preview: Cytokinetics (CYTK) Q4 earnings expected to decline
This article provides an earnings preview for Cytokinetics (CYTK) Q4, anticipating a decline in earnings. It highlights that the Zacks Consensus Estimate for EPS is -$0.82, showing a decrease from the previous year. Revenue is projected to reach $5.75 million, a significant increase year-over-year.
Cytokinetics Gains EU MYQORZO Approval As Market Weighs Valuation Upside
Cytokinetics (NasdaqGS:CYTK) has received approval from the European Commission for MYQORZO (aficamten) to treat symptomatic obstructive hypertrophic cardiomyopathy in adults across the EU. This regulatory milestone marks the company's transition into commercial activity in a major healthcare market with an approved cardiovascular product. The market is now evaluating the valuation upside, considering the company's current financial position (loss-making) against the potential revenue from this new approval.
Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market
Cytokinetics has received marketing authorization from the European Commission for its heart failure drug, MYQORZO (aficamten), completing a global regulatory "triple crown" after prior approvals in the US and China. This approval expands the company's cardiovascular franchise into the European market, positioning it as a significant player in treating obstructive hypertrophic cardiomyopathy (oHCM). The move shifts Cytokinetics to a commercial execution story, challenging competitors like Bristol Myers Squibb, and its shares have already seen a substantial surge based on anticipated regulatory victories.
Skandinaviska Enskilda Banken AB publ Boosts Position in Cytokinetics, Incorporated $CYTK
Skandinaviska Enskilda Banken AB publ significantly increased its stake in Cytokinetics, Incorporated, acquiring over 110,000 additional shares to hold a total of 149,957 shares valued at $8.24 million. This move is alongside other institutional investments and insider selling activity, with analysts maintaining a largely positive outlook for Cytokinetics, evidenced by multiple "Buy" ratings and upward revised price targets. Cytokinetics, a biopharmaceutical company, focuses on developing therapeutics for muscle function modulation, with its most advanced program targeting heart failure treatment.
Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth
Truist has raised its price target for Cytokinetics, Incorporated (CYTK) to $92 from $84, maintaining a Buy rating. This adjustment reflects operational investments, including a drug's free supply program, the annual WAC price for Myqorzo, and anticipated increased operational costs in 2026 to support short-term growth. The company also announced the commercial availability of MYQORZO (aficamten) in the U.S. for treating obstructive hypertrophic cardiomyopathy (oHCM).
Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth
Truist has raised its price target for Cytokinetics (CYTK) to $92 from $84, maintaining a Buy rating, ahead of its Q4 results. This adjustment accounts for the impact of a free drug supply program, the annual WAC price for Myqorzo, and increased operational costs anticipated for 2026. Cytokinetics recently launched MYQORZO (aficamten) in the U.S. for treating obstructive hypertrophic cardiomyopathy (oHCM), marking its entry into the commercial biopharmaceutical stage.
Cytokinetics Faces Governance Inquiry As Aficamten Delay Meets Undervalued Stock
Cytokinetics (NasdaqGS:CYTK) is under scrutiny due to a formal investigation into potential breaches of fiduciary duty by its directors and officers. This inquiry stems from an alleged omission in the New Drug Application for aficamten, reportedly causing a three-month delay in FDA approval and raising concerns about the company's governance and regulatory oversight. The investigation comes as Cytokinetics is considered undervalued by Simply Wall St, despite recent positive stock performance.
Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline
Cytokinetics (CYTK) is anticipated to report a year-over-year decline in Q4 earnings and revenues for the quarter ended December 2025. The company is expected to post a quarterly loss of $1.48 per share, a 17.5% decrease, and revenues of $3.89 million, down 77%. The Zacks Earnings ESP indicates a potential earnings miss due to analysts recently becoming more bearish on the company's prospects.
Cytokinetics Receives European Commission Approval for MYQORZO® (aficamten) to Treat Obstructive Hypertrophic Cardiomyopathy; Launch Planned in Germany for Q2 2026
Cytokinetics has received European Commission approval for MYQORZO® (aficamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults. The approval is based on positive results from the SEQUOIA-HCM clinical trial, showing improved exercise capacity. The drug is expected to launch first in Germany in Q2 2026, expanding treatment options for patients in the EU.
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics announced that the European Commission (EC) has approved MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. This approval is based on positive results from the SEQUOIA-HCM clinical trial, demonstrating significant improvements in exercise capacity and symptoms. The company plans its first European launch in Germany in Q2 2026, offering a new treatment option for patients with oHCM.
New MYQORZO drug wins EU nod to treat symptomatic obstructive HCM
Cytokinetics has received European Commission approval for MYQORZO (aficamten) tablets to treat symptomatic obstructive hypertrophic cardiomyopathy (NYHA class II-III) in adults. The first European launch is planned for Germany in Q2 2026, with flexible dosing options. This approval follows prior FDA and China NMPA approvals, broadening the drug's global reach, and is based on positive results from the SEQUOIA-HCM Phase 3 clinical trial.
Cytokinetics (CYTK) Expected to Announce Earnings on Tuesday
Cytokinetics (CYTK) is scheduled to announce its Q4 2025 earnings after market close on Tuesday, February 24th, 2026. Analysts currently project a loss of ($1.48) per share and revenue of $8.023 million for the quarter. Insider selling has been observed recently, with executives and directors selling shares, while institutional investors have adjusted their positions. The stock holds a "Moderate Buy" consensus rating from analysts, with an average price target of $87.42.
Cytokinetics Reports EC Approval of Myqorzo for Obstructive Hypertrophic Cardiomyopathy
Cytokinetics announced that the European Commission (EC) has approved MYQORZO for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) and marks a significant step for patients in the EU suffering from this debilitating cardiac condition. MYQORZO (aficamten) is a cardiac myosin inhibitor developed by Cytokinetics.
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics announced that the European Commission has approved MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. This approval, based on positive results from the SEQUOIA-HCM clinical trial, marks an important milestone towards making MYQORZO available in Europe, with the first launch expected in Germany in Q2 2026. MYQORZO is a cardiac myosin inhibitor designed to reduce cardiac contractility and left ventricular outflow tract obstruction in oHCM patients.
CYTOKINETICS INC (NASDAQ:CYTK) Shows Strong Technicals and High-Quality Breakout Setup
CYTOKINETICS INC (NASDAQ:CYTK) exhibits strong technicals with a high Technical Rating of 8 out of 10, indicating a positive environment with sustained buying interest and a firm uptrend validated by rising moving averages and strong relative performance. The stock also presents a high-quality breakout setup, scoring 9 out of 10, characterized by a recent consolidation phase between $60 and $68. This setup includes clear support and resistance levels, a "Pocket Pivot" buying signal, and a defined trade plan with a proposed entry at $68.16 and a stop-loss at $61.25.
Cytokinetics Faces Governance Inquiry As Aficamten Delay Meets Undervalued Stock
Cytokinetics (NasdaqGS:CYTK) is under scrutiny due to a formal investigation into potential breaches of fiduciary duty by its directors and officers. The inquiry stems from an alleged omission in the New Drug Application for aficamten, reportedly causing a three-month FDA approval delay. This governance issue arises as the stock has seen significant gains, and it introduces new risk factors for investors, prompting questions about management oversight and future regulatory decisions.
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
Cytokinetics, Incorporated announced it is scheduled to report its fourth-quarter results on February 24, 2026, at 4:00 PM Eastern Time. Following the announcement, senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates, which will be webcast on the company's website. The company also provided an overview of its pipeline, including MYQORZO™ (aficamten) for hypertrophic cardiomyopathy, and investigational medicines omecamtiv mecarbil and ulacamten for heart failure.
Cytokinetics Faces Governance Inquiry As Aficamten Delay Meets Undervalued Stock
Cytokinetics is under scrutiny due to a formal investigation into potential breaches of fiduciary duty by its directors and officers. This inquiry stems from an alleged omission in the New Drug Application for aficamten, which reportedly caused a three-month delay in FDA approval for the drug. The stock, currently trading significantly below its analyst target and Simply Wall St's fair value estimate, faces new risks alongside its existing financial challenges.
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
Cytokinetics, Incorporated announced it is scheduled to report fourth-quarter results on February 24, 2026, at 4:00 PM Eastern Time. Following the announcement, senior management will host a conference call at 4:30 PM ET to discuss financial results and provide business updates, which will be webcast on the company's website. Cytokinetics is a specialty cardiovascular biopharmaceutical company focused on developing new medicines for cardiac muscle dysfunction, including MYQORZO™ (aficamten) which is already approved in the U.S. and China for obstructive HCM.
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
Cytokinetics, Incorporated will announce its fourth-quarter results on February 24, 2026, at 4:00 PM Eastern Time. Following the announcement, senior management will host a conference call to discuss financial results and provide business updates, which will also be webcast. The company specializes in cardiovascular biopharmaceuticals, with an approved cardiac myosin inhibitor, MYQORZO™, for symptomatic obstructive hypertrophic cardiomyopathy and other investigational drugs in its pipeline.
Cytokinetics Gets 'On Track' With Campaign For Cardio Condition 02/11/2026
Cytokinetics has launched an awareness campaign called "On Track with HCM" for hypertrophic cardiomyopathy (HCM), featuring Olympic gold medalist Sydney McLaughlin-Levrone and her father, an HCM patient. This campaign coincides with the launch of Myqorzo, Cytokinetics' first consumer drug, and aims to drive awareness and expand the market for HCM treatments, particularly among undiagnosed patients. The campaign focuses on patient and caregiver education through various media channels, including videos on living with HCM, and complements branded marketing for Myqorzo.
The Bull Case For Cytokinetics (CYTK) Could Change Following MYQORZO Progress And HCM Advocacy Grants
Cytokinetics recently announced the approval of MYQORZO (aficamten) for symptomatic obstructive HCM and its marketing review status in the EU, alongside awarding grants to hypertrophic cardiomyopathy patient advocacy groups. This move ties the company's commercial goals to disease awareness and patient engagement. The article examines how MYQORZO's regulatory progress and HCM-focused advocacy grants will influence Cytokinetics' investment narrative and future risk profile, emphasizing the importance of successful commercial execution and managing costs for the company's growth.
Cytokinetics Gets 'On Track' With Campaign For Cardio Condition
Cytokinetics has launched an awareness campaign called "On Track with HCM" for hypertrophic cardiomyopathy (HCM), featuring Olympic gold medalist Sydney McLaughlin-Levrone and her father, who is an HCM patient. This campaign coincides with the launch of Myqorzo, Cytokinetics' first consumer product, an HCM drug. The awareness effort differentiates itself from an earlier campaign by solely targeting patients and caregivers for HCM, a leading cause of sudden cardiac death.
Cytokinetics, Incorporated (NASDAQ: CYTK) Long Term Investor Alert: Investigation of potential Wrongdoing
An investigation has been launched on behalf of long-term investors in Cytokinetics, Incorporated (NASDAQ: CYTK) concerning potential breaches of fiduciary duties by the company's directors and officers. This follows a lawsuit alleging securities law violations related to the New Drug Application for aficamten, specifically claims that the company knowingly omitted a Risk Evaluation and Mitigation Strategy, causing a three-month FDA approval delay. Current long-term investors are encouraged to contact the Shareholders Foundation for options regarding their investment.
Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Boston Scientific (BSX)
J.P. Morgan and Citi analysts have recently reiterated Buy ratings on Cytokinetics (CYTK) and Boston Scientific (BSX) respectively, expressing bullish sentiments for these healthcare stocks. Cytokinetics has a Strong Buy consensus with a significant upside potential, while Boston Scientific also holds a Strong Buy consensus with a target price reflecting a notable upside. These recommendations highlight positive outlooks from financial experts on the future performance of both companies.
Cytokinetics (CYTK) Valuation Check After Recent Share Price Moves And Aficamten Expectations
Cytokinetics (CYTK) has seen recent share price moves and attention due to its late-stage muscle-focused drug pipeline, particularly Aficamten. The stock is currently valued at $62.34, with a most popular narrative suggesting it is 22% undervalued with a fair value of $79.56 per share, contingent on the success of Aficamten. This valuation relies on specific assumptions about trial success, commercialization, and profitability.
Cytokinetics Announces Recipients Of Its Eighth Annual Communications Grant Program
Cytokinetics has announced the recipients of its eighth annual Communications Grant Program. This news was published by Reuters and Refinitiv and is a brief update regarding the company's activities.
Physician Views Preview: Can BMS's Camzyos fend off competition from Cytokinetics' Myqorzo in oHCM?
This article provides a preview of physician views on the competitive landscape for obstructive hypertrophic cardiomyopathy (oHCM). It focuses on whether Bristol Myers Squibb's (BMS) Camzyos can maintain its market position against upcoming competition from Cytokinetics' Myqorzo. The analysis will likely delve into perceived efficacy, patient profiles, and market strategies for both drugs.
New campaigns give HCM patients, families stronger voices
Cytokinetics (Nasdaq: CYTK) announced the recipients of its eighth annual Communications Grant Program, awarding two grants to patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM). These grants will fund digital communications, bilingual video resources, a pediatric clinic toolkit, and a Canadian awareness campaign to enhance HCM education and community engagement. The initiative aims to amplify patient voices and strengthen community connections, complementing Cytokinetics' past regulatory and commercial efforts, including the FDA approval of MYQORZO.
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
Cytokinetics announced the recipients of its eighth annual Communications Grant Program, awarding two grants to patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM). Camp Taylor will create a digital communications initiative called "Living with HCM: Youth Voices from Camp Taylor," including a video series and toolkit. The Canadian Sudden Arrhythmia Death Syndrome (SADS) Foundation will develop "Think. Know. Act.: Cardiomyopathy Awareness in Canada," a 360-degree digital campaign to raise awareness and foster community engagement for Canadian families affected by HCM.
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Cytokinetics, Incorporated (NASDAQ:CYTK) on behalf of investors who purchased securities prior to December 27, 2023, and still hold them. The investigation focuses on whether the company or its officers engaged in corporate wrongdoing. The law firm encourages affected investors to contact them for more information and to assist with the investigation.
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Cytokinetics, Incorporated (NASDAQ:CYTK) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $87.42. Despite this, company insiders have been net sellers, divesting 163,760 shares worth approximately $10.62 million in the last three months. The biopharmaceutical company recently reported an EPS beat but missed revenue estimates, with its stock trading around $60 and a market cap of about $7.37 billion.
MYQORZO Approval Shifts Cytokinetics Toward Commercial Growth And Valuation Upside
Cytokinetics (NasdaqGS:CYTK) has received FDA approval for MYQORZO (aficamten) as a treatment for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the U.S., initiating its commercial launch. This marks a significant shift for the company from development to commercialization, introducing its first FDA-approved product and a personalized patient support program. While the stock currently trades below analyst targets and Simply Wall St's fair value estimate, the company faces execution risk as it transitions from being loss-making with negative shareholders' equity.
Cytokinetics stock maintains Buy rating at B.Riley amid strong CMI market
B.Riley has maintained a Buy rating and a $108.00 price target for Cytokinetics (NASDAQ:CYTK) following the launch of its drug, Myqorzo, which is expected to compete effectively in the cardiac myosin inhibitor (CMI) market. Myqorzo offers streamlined administration compared to Bristol Myers Squibb's CAMZYOS, potentially allowing it to quickly capture market share, including a significant pool of switched patients and new diagnoses. Other analysts have also reacted positively to Myqorzo's FDA approval and market potential, setting price targets that reflect optimism for the company's future.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into Cytokinetics, Incorporated (CYTK) concerning potential corporate wrongdoing. The firm is encouraging shareholders who purchased Cytokinetics securities before December 27, 2023, and still hold them, to connect and assist with the investigation. The legal firm specializes in representing investors in securities fraud class actions and shareholder derivative suits, aiming to recover investor capital and ensure corporate accountability.
Cytokinetics, Incorporated (CYTK): A Bull Case Theory
This article summarizes a bullish thesis on Cytokinetics, Incorporated (CYTK), focusing on its lead drug Aficamten for hypertrophic cardiomyopathy (HCM). The drug shows strong clinical data, potential for premium pricing and significant peak sales, aiming to be a next-in-class therapy with advantages over competitors. Despite cooled acquisition speculation, Cytokinetics is well-capitalized for independent launch and profitability by 2026, with key catalysts like upcoming PDUFA decisions and sales ramps offering a compelling investment opportunity.
Cytokinetics, Incorporated (CYTK): A Bull Case Theory
This article summarizes a bullish thesis on Cytokinetics, Incorporated (CYTK) from Valueinvestorsclub.com, focusing on their lead drug Aficamten for hypertrophic cardiomyopathy (HCM). Aficamten's strong clinical data, potential advantages over competitors, and estimated multi-billion dollar peak sales position it for significant growth. Despite cooled acquisition speculation, Cytokinetics is well-capitalized for an independent launch, with key catalysts including a December 2025 PDUFA decision and a sales ramp in 2026-2027.
Truist Securities Raises Price Target for CYTK with Buy Rating
Truist Securities has reiterated its Buy rating for Cytokinetics (CYTK) and increased its price target from $84.00 to $92.00, indicating a 9.52% increase. This adjustment reflects continued confidence in the company, which is a late-stage biopharmaceutical firm focused on developing treatments for debilitating diseases involving compromised muscle performance. The average target price from 17 analysts is $89.76, suggesting a 37.76% upside from its current price, while GuruFocus estimates a fair value of $402.14, implying a 517.16% upside.
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Play with a 41.55% Upside Potential
Cytokinetics (NASDAQ: CYTK), a biotechnology company focused on muscle activators and inhibitors, shows strong potential with a 41.55% upside to its average analyst target price of $89.44. Despite negative EPS and free cash flow common for clinical-stage biotechs, the company boasts 318.10% revenue growth and a promising pipeline including Phase III drugs for heart failure and hypertrophic cardiomyopathy. Analyst sentiment is overwhelmingly positive, suggesting CYTK is a compelling opportunity for risk-tolerant investors in the healthcare sector.
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 886 Shares
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos recently sold 886 shares of the company's stock for $55,020.60, reducing his stake by 1.73% to 50,440 shares. This transaction follows several other significant sales by Callos in December and January, indicating a pattern of insider liquidation. The stock is currently trading in the mid-$60s with a market cap of approximately $7.97 billion, and analysts have a consensus "Moderate Buy" rating with an average target price of $87.00.
Universal Beteiligungs und Servicegesellschaft mbH Sells 444,464 Shares of Cytokinetics, Incorporated $CYTK
Universal Beteiligungs und Servicegesellschaft mbH significantly reduced its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by selling 444,464 shares, a 93.5% decrease, now holding 30,707 shares valued at $1.688 million. This comes as company insiders have been net sellers, offloading over 150,000 shares, while Cytokinetics reported a Q3 EPS of -$1.54, beating estimates, but revenue of $1.94 million missed expectations. Analysts currently rate the stock a "Moderate Buy" with an $87 target price.
J. Safra Sarasin Holding AG Sells 43,723 Shares of Cytokinetics, Incorporated $CYTK
J. Safra Sarasin Holding AG significantly reduced its stake in Cytokinetics, Incorporated, selling 43,723 shares, which represents a 64.1% decrease, leaving them with 24,467 shares valued at $1.345 million. This divestment comes as Cytokinetics launched its first commercial product, MYQORZO, in the U.S. after FDA approval, though its distribution is under a restricted REMS program. Insiders also sold a substantial number of shares, while various analysts have issued mixed ratings on the stock.
Halozyme buys a biotech startup; Cytokinetics launches heart drug
Halozyme Therapeutics acquired Surf Bio for up to $400 million, enhancing its drug delivery technology for subcutaneous injections. Cytokinetics launched its heart drug Myqorzo in the U.S. at an annual list price of $108,400, directly competing with Bristol Myers Squibb's Camzyos. Other industry news includes Boehringer Ingelheim securing rights to an inflammatory bowel disease drug from Simcere Pharmaceutical Group, GSK's RSV vaccine receiving broadened approval in Europe, and Epidarex Capital closing $145 million in funding for life sciences startups.
Cardiac Myosin Inhibitor Now Available for Treating Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics, Inc. has announced the availability of Myqorzo (aficamten) in the U.S. for prescription, treating adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Approved by the FDA, this cardiac myosin inhibitor aims to improve functional capacity and symptoms. The drug is available in various tablet strengths, and its launch marks Cytokinetics' transition into a commercial biopharmaceutical company, following extensive research and clinical development.
Cytokinetics (CYTK) Receives Overweight Rating from Barclays, PT Set at $87 | CYTK Stock News
Barclays has initiated coverage on Cytokinetics (CYTK) with an Overweight rating and an $87 price target. This follows recent positive analyst ratings and price target increases from other firms like RBC Capital, B. Riley Securities, JP Morgan, Morgan Stanley, and HC Wainwright & Co., signaling a strong growth outlook for the biopharmaceutical company. Cytokinetics specializes in developing muscle activators and inhibitors for debilitating diseases, and analysts project an average target price of $89.76, implying a significant upside from its current price.
Halozyme buys a biotech startup; Cytokinetics launches heart drug
Halozyme Therapeutics has acquired Surf Bio for an upfront payment of $300 million, aiming to enhance its drug delivery capabilities. Meanwhile, Cytokinetics has officially launched its heart drug Myqorzo in the U.S. to compete with Bristol Myers Squibb's Camzyos. The article also includes updates on Boehringer Ingelheim, GSK, and Epidarex Capital's recent activities.
Need To Know: The Consensus Just Cut Its Cytokinetics, Incorporated (NASDAQ:CYTK) Estimates For 2026
Analysts have downgraded their 2026 revenue forecasts for Cytokinetics, Incorporated (NASDAQ:CYTK) and increased their loss per share estimates. The new consensus predicts revenues of US$124m, a 42% increase from the past year, but higher losses at US$6.00 per share. Despite the downgrade, Cytokinetics is still expected to experience significant growth, outpacing the broader industry.
CYTK - Cytokinetics Inc Latest Stock News & Market Updates
This page provides the latest news and market updates for Cytokinetics Inc. (CYTK), a biopharmaceutical company specializing in cardiovascular treatments. Recent news highlights include awareness campaigns for hypertrophic cardiomyopathy, the availability of MYQORZO™ (aficamten) in the U.S., and inducement equity grants. The company also announced its participation in the J.P. Morgan Healthcare Conference and previous FDA approval for MYQORZO™ in December 2025.
